CN106459221B - 单链trail受体激动剂蛋白 - Google Patents

单链trail受体激动剂蛋白 Download PDF

Info

Publication number
CN106459221B
CN106459221B CN201580031858.7A CN201580031858A CN106459221B CN 106459221 B CN106459221 B CN 106459221B CN 201580031858 A CN201580031858 A CN 201580031858A CN 106459221 B CN106459221 B CN 106459221B
Authority
CN
China
Prior art keywords
ser
gly
leu
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580031858.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459221A (zh
Inventor
O.希尔
C.吉菲尔斯
M.蒂曼
F.G.布查南
D.C.菲利普斯
S.E.拉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
AbbVie Inc
Original Assignee
Apogenix AG
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix AG, AbbVie Inc filed Critical Apogenix AG
Priority to CN202010767219.XA priority Critical patent/CN111718424A/zh
Publication of CN106459221A publication Critical patent/CN106459221A/zh
Application granted granted Critical
Publication of CN106459221B publication Critical patent/CN106459221B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
CN201580031858.7A 2014-04-23 2015-04-23 单链trail受体激动剂蛋白 Expired - Fee Related CN106459221B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010767219.XA CN111718424A (zh) 2014-04-23 2015-04-23 单链trail受体激动剂蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
US61/983152 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010767219.XA Division CN111718424A (zh) 2014-04-23 2015-04-23 单链trail受体激动剂蛋白

Publications (2)

Publication Number Publication Date
CN106459221A CN106459221A (zh) 2017-02-22
CN106459221B true CN106459221B (zh) 2020-09-01

Family

ID=53055121

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010767219.XA Pending CN111718424A (zh) 2014-04-23 2015-04-23 单链trail受体激动剂蛋白
CN201580031858.7A Expired - Fee Related CN106459221B (zh) 2014-04-23 2015-04-23 单链trail受体激动剂蛋白

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010767219.XA Pending CN111718424A (zh) 2014-04-23 2015-04-23 单链trail受体激动剂蛋白

Country Status (38)

Country Link
US (5) US9908927B2 (enExample)
EP (2) EP3366699A1 (enExample)
JP (2) JP6523331B2 (enExample)
KR (2) KR102079919B1 (enExample)
CN (2) CN111718424A (enExample)
AR (1) AR100168A1 (enExample)
AU (3) AU2015249649B2 (enExample)
BR (1) BR112016024515B1 (enExample)
CA (2) CA2946402C (enExample)
CL (1) CL2016002683A1 (enExample)
CR (1) CR20160516A (enExample)
CY (1) CY1120281T1 (enExample)
DK (1) DK3134430T3 (enExample)
DO (1) DOP2016000284A (enExample)
EC (1) ECSP16089579A (enExample)
ES (1) ES2672368T3 (enExample)
HR (1) HRP20180950T1 (enExample)
HU (1) HUE038914T2 (enExample)
IL (2) IL248244B (enExample)
LT (1) LT3134430T (enExample)
MA (2) MA39770A (enExample)
MX (2) MX2016013858A (enExample)
MY (1) MY181986A (enExample)
NO (1) NO2776305T3 (enExample)
PE (1) PE20170299A1 (enExample)
PH (2) PH12020500377A1 (enExample)
PL (1) PL3134430T3 (enExample)
PT (1) PT3134430T (enExample)
RS (1) RS57153B1 (enExample)
RU (1) RU2699285C2 (enExample)
SG (3) SG10202111785VA (enExample)
SI (1) SI3134430T1 (enExample)
SM (1) SMT201800286T1 (enExample)
TR (1) TR201806912T4 (enExample)
TW (2) TWI683825B (enExample)
UA (1) UA118286C2 (enExample)
UY (1) UY36095A (enExample)
WO (1) WO2015164588A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023646A2 (pt) 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
AU2016342420B2 (en) 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
WO2017151707A1 (en) 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
WO2017161173A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3468580A4 (en) * 2016-06-13 2020-02-26 Merrimack Pharmaceuticals, Inc. METHODS OF SELECTING AND TREATING PATIENTS WITH A CELL DEATH RECEPTOR AGONIST OR A TRAIL-BASED THERAPEUTIC COMPOUND
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
WO2019032952A1 (en) 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2021229103A2 (en) 2020-05-15 2021-11-18 Apogenix Ag Multi-specific immune modulators
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
CN102369291A (zh) * 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
WO2013092983A2 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
WO2002046227A2 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
ES2333358T3 (es) 2005-04-15 2010-02-19 Rappaport Family Institute For Research In The Medical Sciences Moleculas y metodos de uso de las mismas para el tratamiento de enfermedades asociadas con mcp-1/ccr2.
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP3072903B1 (en) 2007-07-10 2017-10-25 Apogenix AG Tnf superfamily collectin fusion proteins
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009293545A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
AU2009303304A1 (en) * 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
JP5844158B2 (ja) 2009-01-09 2016-01-13 アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ 三量体形成融合タンパク質
CN102939303A (zh) * 2009-12-22 2013-02-20 诺瓦提斯公司 四价cd47-抗体恒定区融合蛋白用于治疗
BR112012026003B1 (pt) * 2010-04-13 2022-03-15 Medimmune, Llc Estrutura multimérica recombinante específica trail r2, seu uso, bem como composição
CA2878992C (en) 2012-07-18 2020-09-22 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
CN102369291A (zh) * 2009-01-23 2012-03-07 比奥根艾迪克Ma公司 效应子功能降低的稳定Fc多肽及使用方法
WO2013092983A2 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Effi cacy Independent of Cross-Linking via Fc g Receptors;Christian Gieffers 等;《Molecular Cancer Therapeutics》;20131007;第12卷(第12期);第2735-2748页 *
Death receptor agonist therapies for cancer, which is the right TRAIL?;Pamela M. Holland;《Cytokine & Growth Factor Reviews》;20131224;第25卷(第2期);第185-193页 *
Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity;Haizhen Wang 等;《Molecular Cancer Therapeutics》;20140115;第13卷(第3期);第643-651页 *

Also Published As

Publication number Publication date
JP6523331B2 (ja) 2019-05-29
ECSP16089579A (es) 2018-05-31
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
SMT201800286T1 (it) 2018-07-17
UA118286C2 (uk) 2018-12-26
NO2776305T3 (enExample) 2018-01-27
AU2020202247A1 (en) 2020-04-23
EP3366699A1 (en) 2018-08-29
SG10202111785VA (en) 2021-12-30
US9908927B2 (en) 2018-03-06
PT3134430T (pt) 2018-04-20
JP6714751B2 (ja) 2020-06-24
JP2019162114A (ja) 2019-09-26
MX2019013587A (es) 2020-01-13
UY36095A (es) 2015-10-30
CA2946402C (en) 2023-02-28
IL272612A (en) 2020-03-31
MA39770A (fr) 2015-10-29
IL248244B (en) 2020-03-31
PE20170299A1 (es) 2017-05-06
AU2015249649A1 (en) 2016-11-10
WO2015164588A1 (en) 2015-10-29
AR100168A1 (es) 2016-09-14
KR20190135546A (ko) 2019-12-06
RU2016145608A3 (enExample) 2018-12-26
DK3134430T3 (en) 2018-05-22
SG10201806465TA (en) 2018-08-30
KR102079919B1 (ko) 2020-02-24
JP2017513503A (ja) 2017-06-01
CY1120281T1 (el) 2019-07-10
KR20170012257A (ko) 2017-02-02
SG11201608767XA (en) 2016-11-29
US20180222962A1 (en) 2018-08-09
TW201620928A (zh) 2016-06-16
EP3134430A1 (en) 2017-03-01
NZ725476A (en) 2023-09-29
US20250145688A1 (en) 2025-05-08
PH12016502079A1 (en) 2016-12-19
BR112016024515A2 (pt) 2017-10-10
RS57153B1 (sr) 2018-07-31
CA2946402A1 (en) 2015-10-29
IL248244A0 (en) 2016-11-30
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
DOP2016000284A (es) 2017-02-15
CL2016002683A1 (es) 2017-07-07
MA45069A (fr) 2019-04-03
BR112016024515B1 (pt) 2020-03-31
SI3134430T1 (en) 2018-05-31
AU2018271369A1 (en) 2018-12-20
RU2016145608A (ru) 2018-05-28
EP3134430B1 (en) 2018-03-21
US20210040178A1 (en) 2021-02-11
CR20160516A (es) 2017-05-10
ES2672368T3 (es) 2018-06-14
AU2015249649B2 (en) 2018-10-04
PH12020500377A1 (en) 2022-11-14
MX2016013858A (es) 2017-08-02
MY181986A (en) 2021-01-18
TR201806912T4 (tr) 2018-06-21
PL3134430T3 (pl) 2018-08-31
RU2699285C2 (ru) 2019-09-04
TWI747178B (zh) 2021-11-21
US20240174731A1 (en) 2024-05-30
LT3134430T (lt) 2018-05-10
TWI683825B (zh) 2020-02-01
TW202024123A (zh) 2020-07-01
HUE038914T2 (hu) 2018-12-28
PH12016502079B1 (en) 2016-12-19
US20150337027A1 (en) 2015-11-26
HRP20180950T1 (hr) 2018-08-10

Similar Documents

Publication Publication Date Title
US20250145688A1 (en) Single-chain trail-receptor agonist proteins
US10793616B2 (en) Single-chain CD40-receptor agonist proteins
US20210246190A1 (en) Single-chain cd137-receptor agonist proteins
US10683332B2 (en) Single-chain light receptor agonist proteins
AU2016341402B2 (en) Single-chain GITR-receptor agonist proteins
HK1260151A1 (en) Single-chain trail-receptor agonist proteins
HK1235072A1 (en) Single-chain trail-receptor agonist proteins
HK1235072B (en) Single-chain trail-receptor agonist proteins
NZ725476B2 (en) Single-chain trail-receptor agonist proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200901

CF01 Termination of patent right due to non-payment of annual fee